

Artimplant AB Hulda Mellgrens gata 5 SE-421 32 Västra Frölunda SWEDEN

 Phone
 +46 (0)31 746 56 00

 Fax
 +46 (0)31 746 56 60

 Web
 www.artimplant.com

 Org. No
 556404-8394

Press Release Västra Frölunda, Sweden, January 30, 2007

# First case studies on Artelon<sup>®</sup> foot applications

# At the 2007 annual meeting for the Swedish Society of Foot Surgeons case studies on Artelon<sup>®</sup> foot applications were presented.

Dr. Liliane Helger at Sahlgrenska University Hospital Mölndal (SU) presented the first clinical case reports on spring ligament repair with Artelon<sup>®</sup> Tissue Reinforcement<sup>\*</sup>. The first patient received treatment in March 2006. All patients have been successfully treated without complications to date. Dr. Helger also reported that she has treated a patient suffering from osteoarthritis in the MTP joint with an Artelon<sup>®</sup> MTP Spacer.

In addition, Dr. Jan Lidström, SU, informed about using Artelon<sup>®</sup> Tissue Reinforcement for repair of Achilles tendon rerupture.

# CEO Hans Rosén;

"In accordance with our plan we are collecting data to further widen the use of Artelon<sup>®</sup> Tissue Reinforcement in addition to the main indication - rotator cuff repair. Spring foot ligament and Achilles tendon repair are two very interesting applications where the unique properties of Artelon<sup>®</sup> offers the surgeon new opportunities for unmet clinical needs. The data received so far is very encouraging. The number of cases is still small and it takes time to establish new products on the market. However, the case reports confirm the opportunity to expand the number of indications for Artelon<sup>®</sup> Tissue Reinforcement."

\*Artelon<sup>®</sup> Tissue Reinforcement is marketed in the Nordic countries by Artimplant AB and exclusive in the rest of the world by Arthrotek, Inc., a Biomet Company, under the trademark SportMesh<sup>TM</sup> Soft Tissue Reinforcement for reinforcement of rotator cuff tears.

In Europe, the CE marked Artelon<sup>®</sup> Tissue Reinforcement/SportMesh<sup>™</sup> Soft tissue Reinforcement is intended for use in general surgical procedures for reinforcement of soft tissue. It is also intended for reinforcement of soft tissues that are repaired by suture or suture anchors, during tendon repair surgery including reinforcement of rotator cuff, patellar, Achilles, biceps, quadriceps or other tendons.

In USA SportMesh<sup>TM</sup> Soft Tissue Reinforcement is intended for use in general surgical procedures for reinforcement of soft tissue. It is also intended for reinforcement of soft tissue that is repaired by suture or suture anchors, limited to the supraspinatus, during rotator cuff surgery.

Artelon<sup>®</sup> is a registered trademark of Artimplant AB. SportMesh<sup>™</sup> is a trademark of Arthrotek, Inc.

#### For additional information, please contact:

Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70, hans.rosen@artimplant.com

Web site: www.artimplant.com



Artimplant AB Hulda Mellgrens gata 5 SE-421 32 Västra Frölunda SWEDEN

 Phone
 +46 (0)31 746 56 00

 Fax
 +46 (0)31 746 56 60

 Web
 www.artimplant.com

 Org. No
 556404-8394

# **About Artimplant**

Artimplant restores health by offering degradable implants that regenerate body functions and improve quality of life.

Our products, made from Artelon<sup>®</sup>, meet unmet clinical needs in a growing number of therapy areas. Our motto is "Help the body to heal".

Artimplant is a public company listed on the Nordic Exchange.

# Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.